Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score matched study. Zanghi A, Borriello G, Bonavita S, Fantozzi R, et al. J Neurol 2024;271:4495-4502.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Zanghi A, Borriello G, Bonavita S, Fantozzi R, et al. Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score matched study. J Neurol 2024;271:4495-4502.
PMID: 38704488